Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Fig. 1

Minimal Residual Disease measured by real-time quantitative PCR: allele specific of immunoglobulin heavy chain (IGH) gene rearrangement (two distinct markers) and (below) : KMT2A/AFF1 fusion transcript (% of ABL reference gene). CDVPA : cyclophosphamide, daunorubicin, vincristine, prednisone, asparaginase.

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us